PapersPMID:23733031
Flaxseed in pediatric hyperlipidemia: a placebo-controlled, blinded, randomized clinical trial of dietary flaxseed supplementation for children and adolescents with hypercholesterolemia.
- findings
- 2
- compound
- 1
- endpoints
- 2
- Study, every finding
- RCT · 4 weeks
- Dose studied, every finding
- 30 g flaxseed daily as 2 muffins and 1 slice of bread, 4 weeks
- Population, every finding
- children and adolescents aged 8 to 18 years with hypercholesterolemia (LDL cholesterol 135 to under 193 mg/dL); ground flaxseed versus whole-wheat substitution
No finding here moved its endpoint.
What did not
How to read these marks →“Flaxseed had no attributable effects on total cholesterol (-8.51 mg/dL [-0.22 mmol/L]; 95% CI, -21.66 to 4.25 mg/dL [-0.56 to +0.11 mmol/L]; relative: -4%, 95% CI, -10% to +2%; P = .20), low-density lipoprotein cholesterol (-6.96 mg/dL [-0.18 mmol/L]; 95% CI, -16.63 to 2.71 mg/dL [-0.43 to +0.07 mmol/L]; relative: -5%, 95% CI, -12% to +2%; P = .15), body mass index z score (+0.002; 95% CI, -0.147 to +0.150; relative: +0%, 95% CI, -12% to +12%; P = .30), or total caloric intake (+117 kcal; 95% CI, -243 to +479; relative: +8%, 95% CI, -17% to +33%; P = .52).”
- No detected effect on total cholesterol (TC)
very limited
- No detected effect on LDL cholesterol
very limited
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- children and adolescents with hypercholesterolemia
- Participants
- 32
- Comparator
- placebo
- Duration
- 28 days
- Endpoints measured
- 7